Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

A week after updating their S-1 in search of at least $115 million on the hot biotech IPO market, Poseida Therapeutics says it’s also …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis-backed Po­sei­da is pack­ing in the cash for its next-gen CAR-T work, adding a $110M ven­ture raise on top of its new­ly-re­filed IPO